STONEGATE SYSTEMSMost operators who read FDA warning letters to peptide companies come away with one takeaway: stay off the GLP-1s and you're fine. The Pinnacle Peptides letter exists to break that theory. Here is what it said, what it cited, and what it means for a catalog that has never carried a weight-loss compound.
The letter in one paragraph
On December 12, 2025, FDA's Center for Drug Evaluation and Research issued warning letter MARCS-CMS 719337 to Pinnacle Peptides of Greensboro, North Carolina. The agency had reviewed the company's website and found it offering selective androgen receptor modulators - SARMs - for sale. Every product carried research-only framing. The FDA's position: these are unapproved new drugs being introduced into interstate commerce, in violation of the Federal Food, Drug, and Cosmetic Act. Standard terms followed - respond in 15 business days with corrective actions, or face escalation that can include seizure and injunction without further notice.
Note what is absent. No semaglutide. No tirzepatide. No retatrutide. Not one compound from the weight-loss category that dominated the 2025-2026 enforcement conversation. Pinnacle got a warning letter for a different shelf entirely.
The compounds: S4 Andarine, LGD-4033, MK-2866
The letter named three SARMs by product listing:
| Compound | Also sold as | Regulatory status |
|---|---|---|
| S4 | Andarine | Unapproved new drug - never approved for any use |
| LGD-4033 | Ligandrol | Investigational compound that never completed approval |
| MK-2866 | Ostarine, Enobosarm | Investigational compound that never completed approval |
The "also sold as" column matters more than it looks. The FDA matched code names to compounds without hesitation - MK-2866 and Ostarine are the same molecule to a regulator, and calling it one or the other changes nothing. Vendors who think a catalog number or an in-house nickname creates distance from the underlying compound are wrong, and the 2026 letters made the same point explicitly by piercing vendor code names. A name never changes what the substance is.
The safety language the FDA used
SARMs letters carry harder language than most peptide letters, because the agency has been building a public record on this category since its 2017 consumer warning about SARMs appearing in bodybuilding products. In the Pinnacle letter, the FDA repeated its position that SARMs are associated with serious safety concerns - including liver toxicity and an increased risk of heart attack and stroke - and that these compounds have never been shown safe or effective for any use.
Why does that matter to you as an operator? Because the safety record is what moves a letter from paperwork to priority. When the FDA can point to documented harm signals in a category, it does not need to prove your specific customers were hurt. The category's record does the work, and it makes follow-through - seizure, injunction, referral - easier to justify internally. SARMs, GLP-1 analogs sold outside the drug supply chain, and growth hormone all carry that kind of record. That is exactly why they cluster at the top of enforcement lists.
The statute in plain English
The legal core of the letter is two sections of the FD&C Act, and neither one mentions peptides, SARMs, or research disclaimers:
- Section 505(a) - a "new drug" cannot be introduced into interstate commerce without an approved application. A product becomes a drug through its intended use, which the FDA reads from everything you publish: product names, descriptions, categories, blog posts, social accounts, customer reviews, even the search terms you buy.
- Section 301(d) - the prohibition itself. Introducing that unapproved new drug into interstate commerce is the prohibited act. Shipping a package across a state line completes the violation.
Notice what the statute does not require: no human-use marketing claim on the product page, no dosing chart, no testimonial. Those things make a case easier, but for compounds the FDA has already categorized as drugs with no legitimate research-supply market at retail, the sale itself is the problem. This is the intended-use doctrine at full strength - the disclaimer is one input among hundreds, and for certain compounds no combination of inputs gets you clear.
Why SARMs sit on the do-not-list next to GLP-1s and HGH
We maintain a do-not-list for every store we build - compounds the platform refuses at product creation, in code, no matter who is typing. SARMs are on it, in the same tier as GLP-1 receptor agonists and growth hormone. The logic is the same for all three:
- Approved or investigational drug status. Compounds that are approved drugs, or that entered formal clinical development, get the FDA's strictest reading. LGD-4033 and MK-2866 both went into human trials under pharmaceutical sponsors. That history follows the molecule forever.
- A documented safety record. The 2017 SARMs warning, the ongoing adverse-event reporting, and the liver-toxicity literature give the agency a public-health rationale that survives any research-only framing.
- An obvious consumer market. The FDA is not naive about who buys Ostarine in vial or capsule form from a retail website. When the realistic customer base is bodybuilders rather than institutions with lab protocols, "research use only" reads as a label, not a limitation.
Compare that with compounds like BPC-157 or TB-500 - genuinely gray, genuinely research-stage, with a defensible RUO market if the site is built right. We wrote up where those stand in 2026 separately. The point is that "peptide store" is not one risk profile. It is a catalog of individual compounds, each with its own regulatory history, and one wrong SKU can put the whole business in a letter.
The lesson: enforcement is category-wide, not compound-specific
Line up the letters and the pattern is unmistakable. The Summit Research Peptides letter in 2024 hit a research-peptide vendor before the GLP-1 wave crested. Pinnacle got cited in December 2025 for SARMs. The 2026 letters went after peptide vendors across multiple compound categories at once. The FDA is not working through a list of weight-loss compounds - it is working through a list of unapproved new drugs sold at retail, and it moves category by category as resources and public-health pressure dictate.
That has three practical consequences for an operator:
- "I don't carry GLP-1s" is not a compliance posture. It is one row of a much longer table. SARMs, HGH and its secretagogue cousins with drug histories, aromatase inhibitors, PDE5 inhibitors sold as "research liquids" - all of these have drawn letters or seizures. If your catalog theory begins and ends with avoiding semaglutide, you have checked one box out of dozens.
- The totality of your site is the evidence. Every letter in this series quotes the vendor's own pages back at them. Product copy, category names, meta descriptions, the blog you forgot about. A compliant catalog with sloppy copy still loses. Our peptide website compliance checklist walks the full surface the FDA actually reads.
- The rules keep moving. A compound that felt gray in 2024 can be letter-bait by 2026. Checking your catalog once, at launch, is not a system. Something has to re-check it as the enforcement picture shifts - in our builds that something is code plus a human reviewing monthly, because memory does not scale and the goalposts do not hold still.
Check what you carry against the full do-not-list
If you sell research compounds and you have never systematically compared your catalog to the compounds named in FDA letters - not just GLP-1s, but SARMs, growth hormone, and the rest of the approved-and-investigational tier - that comparison is the single highest-value hour you can spend this month. You can do it by hand against the letters, or you can let our free 60-second audit do the first pass: it scans your live site against the same rulebook we enforce in code across 50+ RUO builds, grades it on screen, and sends the full report to your inbox. Takes about a minute. No signup, no pressure.
Either way, do the pass. Pinnacle's letter is public precisely so that the next vendor cannot say they did not know. The FDA told everyone, in writing, that research-only framing does not shelter SARMs. The operators who read that as "SARMs problem, not my problem" are making the same category error Pinnacle made - assuming enforcement stops at the edge of their own shelf.
This guide is general information for store operators, not legal advice. If you have received a warning letter, talk to an FDA regulatory attorney - the response window is short and the response matters.